This is a preview of subscription content, log in via an institution to check access.
References
Coates PA, Mukherjee S, Luzio S, et al. Pharmacokinetics of a long-acting human insulin analogue (HOE901) in healthy subjects. Diabetes 1995 May; 44 Suppl. 1: 130A
Owens D, Luzio S, Tinbergen J, et al. The absorption of HOE 901 in healthy subjects. Diabetologia 1998 Aug; 4vn1 Suppl. 1: 245
Lepore M, Kurzhals R, Pampaenelli S, et al. Pharmacokinetics and dynamics of s.c. injection of the long-acting insulin glargine (HOE1) of TiDM. Diabetes 1999 May; 48 Suppl. 1: 97
Luzio SD, Owens D, Evans M, et al. Comparison of the SC absorption of HOE 901 and NPH human insulin type 2 diabetic subjects. Diabetes 1999 May; 48 Suppl. 1: 111
Pieber T, Eugene-Jolchine I, Derobert E, et al. Efficacy and safety of HOE 901 in patients with type 1 diabetes: a fourweek randomised, NPH insulin-controlled trial. Diabetes 1998 May; 47 Suppl. 1: 62
Ratner RE, Hirsch IB, Mecca TE, et al. Efficacy and safety of insulin glargine in subjects with type 1 diabetes: a 28 week randomized, NPH insulin-controlled trial. Diabetes 1999 May; 48 Suppl. 1: 120
Rosenstock J, Schwartz S, Clark C, et al. Efficacy and safety of HOE 901 (insulin glargine) in subjects with type 2 DM: a 28-week randomized, NPH insulin-controlled trial. Diabetes 1999 May; 48 Suppl. 1: 100
Linkeschowa R, Heise T, Rave K. Time-action profile of the long-acting insulin analogue HOE901. Diabetes 1999 May; 48 Suppl. 1: 97
Matthews DR, Pfeiffer C, Multicentre HOE901 Research Group. A new long-acting insulin (HOE901) demonstrates less nocturnal hypoglycaemia when compared with protamine insulin in a clinical trial. Diabetologia 1998 Aug; 41 Suppl. 1: 245
Rights and permissions
About this article
Cite this article
Insulin Glargine. Drugs R&D 2, 107–109 (1999). https://doi.org/10.2165/00126839-199902020-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902020-00005